OOIR: Observatory of International Research

Papers

(The H4-Index of Value in Health is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 500 papers]. The publications cover those that have been published in the past four years, i.e., from 2019-12-01 to 2023-12-01.)

Article	Citations
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force	202
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations	190
Value of Information Analysis for Research Decisions—An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force	84
Effects of Lean Healthcare on Patient Flow: A Systematic Review	64
Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing—Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiativ	61
Patient-Reported Outcomes as Independent Prognostic Factors for Survival in Oncology: Systematic Review and Meta-Analysis	58
Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force	57
Managed Entry Agreements: Policy Analysis From the European Perspective	55
Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary	55
Defining Patient Engagement in Research: Results of a Systematic Review and Analysis: Report of the ISPOR Patient-Centered Special Interest Group	54
Being Precise About Precision Medicine: What Should Value Frameworks Incorporate to Address Precision Medicine? A Report of the Personalized Precision Medicine Special Interest Group	52
Use of Real-World Evidence to Support FDA Approval of Oncology Drugs	52
Critical Appraisal of Systematic Reviews With Costs and Cost-Effectiveness Outcomes: An ISPOR Good Practices Task Force Report	45
Advances in Value-Based Healthcare by the Application of Time-Driven Activity-Based Costing for Inpatient Management: A Systematic Review	43
Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where Are We Now?	43
Formal Implementation of Cost-Effectiveness Evaluations in Japan: A Unique Health Technology Assessment System	42
Disparities in Access to Opioid Treatment Programs and Office-Based Buprenorphine Treatment Across the Rural-Urban and Area Deprivation Continua: A US Nationwide Small Area Analysis	41
Disease Burden Attributable to the First Wave of COVID-19 in China and the Effect of Timing on the Cost-Effectiveness of Movement Restriction Policies	39
Past and Current Practice of Patient-Reported Outcome Measurement in Randomized Cancer Clinical Trials: A Systematic Review	38
Distributional Cost-Effectiveness Analysis Comes of Age	38
Quebec Health-Related Quality-of-Life Population Norms Using the EQ-5D-5L: Decomposition by Sociodemographic Data and Health Problems	37
Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis	37
Computing the Expected Value of Sample Information Efficiently: Practical Guidance and Recommendations for Four Model-Based Methods	34
Health Technology Assessment With Diminishing Returns to Health: The Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Approach	33
Vignette-Based Utilities: Usefulness, Limitations, and Methodological Recommendations	33

The Use of Cost-Effectiveness Thresholds for Evaluating Health Interventions in Low- and Middle-Income Countries From 2015 to 2020: A Review	32
Costing the COVID-19 Pandemic: An Exploratory Economic Evaluation of Hypothetical Suppression Policy in the United Kingdom	32
Preferences for e-Mental Health Interventions in Germany: A Discrete Choice Experiment	31
The EQ-HWB: Overview of the Development of a Measure of Health and Wellbeing and Key Results	30
Measurement Properties of the EQ VAS Around the Globe: A Systematic Review and Meta-Regression Analysis	30
Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations	30
Willingness to Accept Trade-Offs Among COVID-19 Cases, Social-Distancing Restrictions, and Economic Impact: A Nationwide US Study	30